Decreased SLCO1B1 transporter function. Moderate risk of statin-induced myopathy with 80 mg based on SLCO1B1 alone.
Important Instructions: Please use CYP2C9 phenotype to select the appropriate recommendation below.
CYP2C9 Normal Metabolizer
Normal CYP2C9 enzyme activity. Normal response expected based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate standard dosing.
CYP2C9 Intermediate Metabolizer
Decreased CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate ≤ 20 mg, if a dose >20 mg is needed, consider alternative statin or combination therapy.
CYP2C9 Poor Metabolizer
Little to no CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate an alternative statin with lower myopathy risk based on SLCO1B1 (refer to figure to choose based on desired potency).